The early 1990s saw the first clinical testing of several therapeutic cancer vaccines. There was great optimism that these vaccines could be used as an alternative therapy for patients who had failed to respond to conventional cancer therapies. This article provides a personal perspective on the cancer vaccine field after being involved with a series of clinical trials in the United Kingdom (Cardiff) starting in the mid 1990s. It will also review the developments in technology and improved knowledge of the immune system that have informed the design of a new generation of cancer vaccine trials that will start in Cardiff in 2012.
Institute of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, UK
This work was presented at Cancer Biomarking Diagnostic Pathology And Transitional Medicine: Past 30 Years. The meeting in Cardiff, Wales, Great Britain, on May 11th, 2012 was in honour of Professor Bharat Jasani upon his Retirement as Chairman at The University of Cardiff.
Sources of Funding: MRC, CR UK, Cancer Research Wales, The Royal Society.
The author declares no conflict of interest.
Reprints: Stephen Man, PhD, Institute of Cancer and Genetics, Cardiff University School of Medicine, Cancer Genetics Building, Heath Park, Cardiff, CF14 4XN, UK (e-mail: firstname.lastname@example.org).
Received October 22, 2012
Accepted December 3, 2012